Physician profile
John Naitoh
NPI 1629010509
$6,174.88
in general payments reported to CMS, 2019-2025
52 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $422 · 2021: $1,290 · 2022: $798 · 2023: $1,003 · 2024: $766 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,781.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $525.69 | 2019-2025 | |
| Coloplast Corp | $508.26 | 2019-2023 | Speedicath, Titan |
| Urogen Pharma, INC. | $409.86 | 2021-2025 | Jelmyto |
| Sumitomo Pharma America, INC. | $379.18 | 2024-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $340.86 | 2019-2023 | Veozah, Myrbetriq |
| Pfizer INC. | $322.95 | 2019-2025 | |
| Antares Pharma, INC. | $250.50 | 2019-2025 | Xyosted |
| Janssen Biotech, INC. | $240.98 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $209.78 | 2019-2024 | |
| Teleflex LLC | $196.72 | 2019-2024 | Urolift |
| Accord Healthcare, INC. | $189.92 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $186.65 | 2021-2025 | Prolaris |
| Verity Pharmaceuticals INC. | $156.54 | 2025 | Trelstar |
| Valencia Technologies Corporation | $151.58 | 2024 | Ecoin Device Kit |
| Myovant Sciences INC. | $151.54 | 2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Naitoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.